Recall Notices

After notification of any recall, Express Scripts will continue processing new and refill prescriptions with product from non-recalled lots or manufacturers, if available.

Ranitidine prescription capsules recall - Avkare Pharmaceuticals

November 21, 2019

On October 25, 2019, Avkare Pharmaceuticals issued a voluntary recall of prescription ranitidine capsules manufactured by Dr. Reddy’s and distributed by AvKare Pharmaceuticals due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient. Learn more

Ranitidine recall – Golden State Medical Supply

November 19, 2019

On November 18, 2019, Golden State Medical Supply (GSM) issued a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient. Learn more

Ranitidine recall – Avkare Pharmaceuticals

November 19, 2019

On November 14, 2019, Avkare Pharmaceuticals issued a voluntary recall of its ranitidine medications due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient. Learn more

Ranitidine recall – Novitium Pharma LLC.

November 01, 2019

On October 25, 2019, Novitium Pharma LLC (Novitium) issued a voluntary recall of Ranitidine 150mg capsules, and 300mg capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient. Learn more

Important recall notice: Ranitidine recall – Sanofi

November 01, 2019

 

Updated: 10/30/19

On October 22, 2019, Sanofi issued a voluntary recall of Zantac OTC (over-the-counter) products due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will mail letters to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Zantac OTC (over-the-counter) Products:

Zantac 150®

Zantac 150® Cool Mint

Zantac 75®

 

Additional information is available on the FDA’s website:

https://www.fda.gov/ety/recalls-market-withdrawals-safety-alerts/sanofi-provides-update-precautionary-voluntary-recall-zantac-otc-us

Important recall notice: Ranitidine recall – Sandoz Inc.

November 01, 2019

Updated: 10/30/19

On September 23, 2019, Sandoz, Inc. announced issued a voluntary recall of all lots of Ranitidine capsules due to an elevated amount of an unexpected impurity (NDMA) found in the active pharmaceutical ingredient.

Express Scripts will mail letters to patients who have received medication impacted by the recall.

The FDA recommends speaking with your prescriber if you want to stop your medication or use an alternative medication.

Product Name

NDC Number

Lot Nbr.

Expiration Date

Date of Manufacture

RANITIDINE 150mg Capsules 500 count

0781-2855-05

HD1862

04/30/2020

04/19/2017

RANITIDINE 150mg Capsules 500 count

0781-2855-05

HP9438

09/30/2020

09/05/2017

RANITIDINE 150mg Capsules 500 count

0781-2855-05

HP9439

09/30/2020

09/06/2017

RANITIDINE 150mg Capsules 500 count

0781-2855-05

HP9440

09/30/2020

09/05/2017

RANITIDINE 150mg Capsules 60 count

0781-2855-60

HC9266

04/30/2020

04/19/2017

RANITIDINE 150mg Capsules 60 count

0781-2855-60

HD1865

04/30/2020

04/19/2017

RANITIDINE 150mg Capsules 60 count

0781-2855-60

HP9441

09/30/2020

09/06/2017

RANITIDINE 150mg Capsules 60 count

0781-2855-60

JK7994

08/31/2021

08/07/2018

RANITIDINE 150mg Capsules 60 count

0781-2855-60

JK8659

08/31/2021

08/07/2018

RANITIDINE 300mg Capsules 30 count

0781-2865-31

HD8625

04/30/2020

04/27/2017

RANITIDINE 300mg Capsules 30 count

0781-2865-31

HD9275

04/30/2020

04/27/2017

RANITIDINE 300mg Capsules 30 count

0781-2865-31

HU2207

08/31/2020

08/24/2017

RANITIDINE 300mg Capsules 30 count

0781-2865-31

HX6676

03/31/2021

03/20/2018

RANITIDINE 300mg Capsules 30 count

0781-2865-31

HX6677

03/31/2021

03/20/2018

Additional information is available on the FDA’s website:

https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-voluntary-recall-ranitidine-hydrochloride-capsules-150mg-and-300mg-due-elevated

The information on this site is not intended to take the place of your doctor or other healthcare professionals. It is a resource to help you make the best decisions and get the most from the medical services available to you. A licensed physician should be consulted for diagnosis and treatment of all medical conditions.